Trials / Completed
CompletedNCT05887999
A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus
A Phase 1, Randomized, Placebo-Controlled, 2-Period, Cross-over, Double- Blind, Single-Dose Study to Evaluate the Effects of LY3532226 on Insulin- Induced Hypoglycemia in Participants With Type 1 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the response of glucagon to insulin-induced low blood sugar after administration of the study drug LY3532226 in participants with type 1 diabetes mellitus (T1DM). The study will also evaluate if LY3532226 helped participants to recover from insulin-induced low blood sugar condition compared to placebo. The study will last approximately 16 weeks excluding screening period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3532226 | Administered subcutaneously (SC). |
| DRUG | Placebo | Administered SC. |
Timeline
- Start date
- 2023-06-12
- Primary completion
- 2024-02-21
- Completion
- 2024-02-21
- First posted
- 2023-06-05
- Last updated
- 2024-03-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05887999. Inclusion in this directory is not an endorsement.